China Pharmaceutical University & Jiangsu Key Laboratory of Oncogenesis and Intervention, Nanjing, Jiangsu, China.
Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Dermatol Ther. 2020 Sep;33(5):e13525. doi: 10.1111/dth.13525. Epub 2020 May 22.
In December 2019, twenty-seven pneumonia patients with unknown causes originated in South China seafood market in Wuhan. The virus infection spread rapidly and swept through China in less than a month. Subsequently, the virus was proven a novel coronavirus and named SARS-CoV-2. The outbreak of novel coronavirus has been determined as a Public Health Emergency of International Concern (PHEIC) by WHO on January 31, 2020. Similar to other coronaviruses like the Middle East Respiratory Syndrome (MERS) CoV and Severe Acute Respiratory Syndrome (SARS) CoV, the novel coronavirus was reported to spread via respiratory droplets and close contact from human to human, which means the virus is highly infectious and dangerous. Unfortunately, till now the virus has spread to over 200 countries/territories/areas around the world and the Coronavirus Disease 2019 (COVID-19) outbreak is continuing to grow. Currently, information sharing and transparency are essential for risk assessment and epidemic control in all endemic areas. In this article, we compared SARS-CoV-2 with SARS-CoV and influenza virus, discussed current researching progress of COVID-19, including clinical characteristics, pathological changes, treatment measures, and so on.
2019 年 12 月,27 例病因不明的肺炎患者起源于武汉华南海鲜市场。病毒感染迅速蔓延,不到一个月就席卷中国。随后,该病毒被证明是一种新型冠状病毒,并被世界卫生组织(WHO)命名为 SARS-CoV-2。2020 年 1 月 31 日,世界卫生组织将新型冠状病毒疫情确定为国际关注的突发公共卫生事件(PHEIC)。与其他冠状病毒(如中东呼吸综合征(MERS)CoV 和严重急性呼吸综合征(SARS)CoV)类似,新型冠状病毒据报道通过呼吸道飞沫和人与人之间的密切接触传播,这意味着该病毒具有高度传染性和危险性。不幸的是,截至目前,该病毒已传播到全球 200 多个国家/地区,2019 年冠状病毒病(COVID-19)疫情仍在持续蔓延。目前,信息共享和透明度对于所有流行地区的风险评估和疫情控制至关重要。在本文中,我们将 SARS-CoV-2 与 SARS-CoV 和流感病毒进行了比较,讨论了 COVID-19 的当前研究进展,包括临床特征、病理变化、治疗措施等。